MEDI4736
D4193C00001
Phase 2 small_molecule completed
Quick answer
MEDI4736 for Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck is a Phase 2 program (small_molecule) at AstraZeneca with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca
- Indication
- Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed